Omezol capsule 20mg
Pro Research Analysisby 
Searched over 200M research papers
Omeprazole 20 mg Capsules: Bioavailability and Bioequivalence Studies
Introduction to Omeprazole 20 mg Capsules
Omeprazole is a widely used proton-pump inhibitor (PPI) that reduces stomach acid production, making it effective for treating various acid-related gastrointestinal disorders. The 20 mg dosage is a common prescription strength, and numerous studies have been conducted to compare the bioavailability and bioequivalence of different formulations of omeprazole capsules.
Bioavailability of Omeprazole 20 mg Capsules
Comparative Studies in Different Populations
Several studies have investigated the bioavailability of omeprazole 20 mg capsules in different populations. For instance, a study conducted in healthy Bangladeshi male subjects compared the bioavailability of Xeldrin®20 (containing omeprazole 22.5% enteric-coated pellets) with Losec®20 (reference product). The study found no significant differences in pharmacokinetic parameters, and both formulations met the FDA criteria for bioequivalence.
Similarly, a study in healthy Algerian volunteers compared two brands of omeprazole 20 mg gastro-resistant capsules. The results indicated that while the AUC values were within the bioequivalence range, the Cmax did not meet the acceptance criteria, suggesting that the formulations were not bioequivalent in the fasting state.
Pharmacokinetic Comparisons
A study comparing omeprazole delayed-release capsules and a simplified omeprazole suspension (SOS) found that after seven days of treatment, the AUC and Cmax values for the capsule were significantly higher than those for the SOS. This indicates that the capsule formulation had better bioavailability.
In another study involving healthy Mexican volunteers, two oral formulations of omeprazole 20 mg capsules were compared. The study concluded that both formulations were bioequivalent based on the rate and extent of absorption.
Bioequivalence of Omeprazole 20 mg Capsules
Regulatory Criteria and Study Designs
Bioequivalence studies typically follow a crossover design, where subjects receive both the test and reference formulations in separate periods. The FDA requires that the 90% confidence intervals for the ratios of pharmacokinetic parameters (AUC and Cmax) fall within the 80-125% range for the formulations to be considered bioequivalent.
A study in asymptomatic duodenal ulcer patients compared the bioavailability of omeprazole 20 mg enteric-coated tablets and capsules. The results showed that the tablet formulation had higher AUC and Cmax values, but both formulations were considered biodynamically equivalent regarding their effects on intragastric pH.
Cross-Population Comparisons
In a study involving healthy Korean male volunteers, two brands of omeprazole 20 mg capsules were compared. The pharmacokinetic parameters were within the bioequivalence range, indicating that both formulations were bioequivalent during the fasting state.
Another study compared the pharmacokinetics of Proceptin® 20 mg capsules and Losec® 20 mg MUPS tablets in healthy subjects. The results showed no significant differences in pharmacokinetic parameters, and both formulations met the regulatory criteria for bioequivalence.
Conclusion
The bioavailability and bioequivalence of omeprazole 20 mg capsules have been extensively studied across different populations and formulations. Most studies have found that various formulations meet the FDA criteria for bioequivalence, although some differences in pharmacokinetic parameters have been observed. These findings support the use of different omeprazole formulations in clinical practice, ensuring effective and consistent treatment for acid-related gastrointestinal disorders.
Sources and full results
Most relevant research papers on this topic